Immunic (NASDAQ:IMUX) Issues Quarterly Earnings Results

Immunic (NASDAQ:IMUX) issued its earnings results on Thursday. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.15), Fidelity Earnings reports.

IMUX stock opened at $8.01 on Friday. The stock has a market cap of $86.77 million, a P/E ratio of -0.23 and a beta of 3.51. Immunic has a 1 year low of $6.00 and a 1 year high of $46.80. The business has a fifty day moving average price of $9.77.

Several brokerages have commented on IMUX. ValuEngine upgraded Immunic from a “hold” rating to a “buy” rating in a research note on Saturday, October 5th. Chardan Capital reiterated a “buy” rating on shares of Immunic in a research note on Thursday, September 19th. Finally, Zacks Investment Research upgraded Immunic from a “sell” rating to a “hold” rating in a research note on Wednesday, October 30th.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

About Immunic

Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.

Further Reading: Analyzing a company’s cash flow statement

Earnings History for Immunic (NASDAQ:IMUX)

Leave a Reply

Your email address will not be published. Required fields are marked *